Edwards Lifesciences Makes Strategic Acquisitions of Corvia Medical, Transcatheter Technologies
Today Edwards Lifesciences Corp. announced that it is acquiring Corvia Medival for $35 million. The company’s InterAtrial Shunt Device is designed to reduce the symptoms or slow the progression of heart failure by providing continuous and dynamic decompression of the left atrium. The technology is the ”first transcatheter device to treat heart failure with preserved or mid-range fraction,” according to an Edwards news release. It has the CE Mark and is currently in an FDA pivotal clinical trial.
Edwards also announced that is acquiring assets of Mitralign, Inc. that includes intellectual property, and related clinical and regulatory experience. The company’s Trialign System is an investigational transcatheter annuloplastry system in the United States that is intended to treat functional and mitral and tricuspid regurgitation.
It’s been a busy 30 days for the company. Last month it acquired CAS Medical Systems for $100 million.
Related Articles
-
The FDA CDRH is seeking input from industry and the public on expanding access to home use medical technologies. The comment period closes on August 30, 2023.
-
Leslie Trigg, CEO of Outset Medical, is the new Chair of The Medical Device Manufacturers Association (MDMA) Board of Directors.
-
Smart hospitals are revolutionizing health care with the help of AI, IoT and robotics. Following are the latest technology and data analytics tools and trends that are helping these hospitals of the future provide safer, more personalized care.
-
2022 is now upon us, hopefully marking the end of a very disruptive couple of years. Global challenges, from supply chain shortages to remote services, have driven digital innovation and change in the way we work across all sectors. The…
